“Patients are truly the highest priority in Takeda values and the core of all our business decisions. It’s not just something we say. We live by these values.”
Heather Huet, Ph.D. is Head of Oncology Strategic Operations, OBU at Takeda. Dr. Huet also serves as Head, Portfolio Strategy and Operations, Oncology R&D at Takeda. She joined the company in 2020 and is focused on portfolio strategy, program execution, managing external alliances and business operations supporting global Oncology R&D.
Prior to joining Takeda, Dr. Huet was Head of Program Leadership and Portfolio Management and a member of the executive team at Unum Therapeutics, a biotechnology company focused on the discovery and clinical development of next-generation engineered cell therapies, where she was responsible for the strategy and execution of clinical-stage-product candidates and managing strategic partnerships.
Prior to joining Unum Therapeutics, Dr. Huet spent 15 years as a lab head at Biogen and Novartis, leading global, cross-functional project teams that progressed novel cell therapy and large-molecule therapeutics from discovery to Phase 1 clinical trials.
Dr. Huet received a BS with Honors from the University of Texas at Austin and a Ph.D. in Virology from Harvard University.